Abmaxis

Abmaxis, Inc. is a privately held biopharmaceutical company. It is dedicated to the discovery, optimization and development of monoclonal antibody (MAb) products for human therapeutics and diagnostics. Our management team with experience in the biotech, pharmaceutical and life science industries. Abmaxis has developed and validated a breakthrough a... ntibody engineering technology platform, Abmaxis in-silico Immunization (AISIMTM), which is used for building an internal product pipeline and for collaborations with global biotech and pharmaceutical partners. The product strategy is to develop a pipeline of products with a spectrum of risk profiles, ranging from next-generation of clinically proven antibody drugs with significantly improved attributes to antibodies against novel targets. Abmaxis collaborates with corporate partners who have proprietary targets or antibodies that require humanization and engineering.Read More